![Daily premix insulin doses (U/kg) in participants at baseline, day 1,... | Download Scientific Diagram Daily premix insulin doses (U/kg) in participants at baseline, day 1,... | Download Scientific Diagram](https://www.researchgate.net/publication/361026095/figure/fig2/AS:1162502620626945@1654173631474/Daily-premix-insulin-doses-U-kg-in-participants-at-baseline-day-1-and-week-26-for.png)
Daily premix insulin doses (U/kg) in participants at baseline, day 1,... | Download Scientific Diagram
BTPEN1 ESYSTA BT Pen User Manual 15_ESYSTA BT Pen B and W UserMan EMPERRA GmbH Digital Diabetes Care
![Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13300-022-01279-z/MediaObjects/13300_2022_1279_Fig3_HTML.png)
Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of
![Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M) | SpringerLink Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13300-022-01255-7/MediaObjects/13300_2022_1255_Fig3_HTML.png)